• metastatic/advanced RCC (mRCC) - 2nd line (L2) 2
• sarcomas
• thyroid cancer
• urothelial cancer (UC) - bladder cancer (BC)

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab plus cabozantinib
• nivolumab based treatment
• nivolumab alone

• versus all
• vs mTOR inhibitors
• vs everolimus
• vs VEGF(R) inhibitor
• vs cabozantinib

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Pathology:  metastatic/advanced RCC (mRCC) - 2nd line (L2);